To assess the anti-tumor effects of our vaccine in future animal experiments, an animal cancer model injected with a breast cancer cell line expressing the NY-SAR-35 antigen must be utilized for a more accurate evaluation and understanding of the potential effectiveness of our vaccine against this type of cancer. Here, FMR1NB is linked to neoplasm.